61 results
Keyword Actrapid Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Actrapid
human insulin, Diabetes Mellitus
Date of authorisation: 07/10/2002, Revision: 17, Authorised, Last updated: 21/10/2020Actrapid Glucose Metabolism Disorders Metabolic … Actrapid … summary for the public Actrapid human insulin This is … -
List item
Opinion on medicine for use outside EU: Actrapid
Insulin human, Diabetes Mellitus, ATC code: A10AC01 Opinion number: H-W-005779, Positive opinion Opinion date: 22/04/2022, Last updated: 22/07/2022Actrapid Diabetes Mellitus … Actrapid: Opinion on medicine for use … EMA/351860/2022 EMEA/H/W/005779 Actrapid (human insulin) An overview … -
List item
News: Facilitating global access to diabetes treatments for non-EU patients
CHMP, Last updated: 22/04/2022diabetes mellitus treatments, Actrapid and Insulatard, for use outside … intended for EU citizens. Actrapid and Insulatard are human … in high-income countries. Actrapid and Insulatard are the thirteenth … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022
CHMP, Last updated: 22/04/2022Actrapid … -
List item
National expert: Francesco Marino, Italian Medicines Agency (updated)
- Declaration of interests - 39.21 KB | PDF
- Curriculum Vitae - 39.61 KB | PDF
-
List item
Human medicine European public assessment report (EPAR): Inpremzia
insulin human (rDNA), Diabetes Mellitus
Date of authorisation: 25/04/2022,
, 
, Withdrawn, Last updated: 20/04/2023
to the reference product Actrapid (human insulin), which is … medicine for Inpremzia is Actrapid. For more information on biosimilar … comparing Inpremzia with Actrapid have shown that the active … -
List item
Human medicine European public assessment report (EPAR): NovoRapid
insulin aspart, Diabetes Mellitus
Date of authorisation: 07/09/1999, Revision: 32, Authorised, Last updated: 22/03/2023 -
List item
Human medicine European public assessment report (EPAR): Velosulin
Insulin human, Diabetes Mellitus
Date of authorisation: 07/10/2002, Revision: 5, Withdrawn, Last updated: 17/04/2009have been used to support Actrapid, another insulin approved … -
List item
Human medicine European public assessment report (EPAR): Monotard
Insulin human, Diabetes Mellitus
Date of authorisation: 07/10/2002, Withdrawn, Last updated: 14/02/2008 -
List item
Human medicine European public assessment report (EPAR): Ultratard
Insulin human, Diabetes Mellitus
Date of authorisation: 07/10/2002, Withdrawn, Last updated: 14/02/2008 -
List item
Human medicine European public assessment report (EPAR): Protaphane
Insulin human, Diabetes Mellitus
Date of authorisation: 07/10/2002, Revision: 18, Authorised, Last updated: 27/10/2020 -
List item
Human medicine European public assessment report (EPAR): Edistride
dapagliflozin propanediol monohydrate, Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic
Date of authorisation: 09/11/2015, Revision: 22, Authorised, Last updated: 30/05/2023 -
List item
Human medicine European public assessment report (EPAR): Forxiga
dapagliflozin propanediol monohydrate, Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic
Date of authorisation: 11/11/2012, Revision: 29, Authorised, Last updated: 28/06/2023 -
List item
Withdrawn application: Combimarv
insulin human, date of withdrawal: 15/11/2012, Initial authorisation, Last updated: 14/12/2012 -
List item
Opinion on medicine for use outside EU: Insulatard
Insulin human (RDNA), Diabetes Mellitus, ATC code: A10AC01 Opinion number: H-W-005780, Positive opinion Opinion date: 22/04/2022, Last updated: 28/07/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 February 2023
European Medicines Agency, Amsterdam, the Netherlands, from 20/02/2023 to 23/02/2023, Last updated: 24/04/2023 -
List item
Sampling and testing (updated)
Last updated: 07/11/2023 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 10/11/2023 -
List item
Management Board meeting: 7-8 June 2023
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2023 to 08/06/2023, Last updated: 15/09/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 10-13 October 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/10/2022 to 13/10/2022, Last updated: 23/11/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 30/11/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2022
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2022 to 22/04/2022, Last updated: 12/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2021 to 22/04/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 March 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/03/2021 to 25/03/2021, Last updated: 07/12/2021